CN1225623A - Inhibition of matrix metalloproteases by acetylene contg. compounds - Google Patents

Abstract

Matrix metalloprotease inhibiting compounds, pharmaceutical compositions thereof and a method of disease treatment using such compounds are presented. The compounds of the invention have the generalized formula (I) where R<15> is selected from the group comprising: HOCH2, MeOCH2, (n-Pr)2NCH2, CH3CO2CH2, EtOCO2CH2, HO(CH2)2, CH3CO2(CH2)2, HO2C(CH2)2, OHC(CH2)3, HO(CH2)4, Ph, 3-HO-Ph, and PhCH2OCH2; and R<16> is (a) or (b). These compounds are useful for inhibiting matrix metalloproteases and, therefore, combating conditions to which MMP's contribute, such as osteoarthritis, rheumatoid arthritis, septic arthritis, periodontal disease, corneal ulceration, proteinuria, aneurysmal aortic disease, dystrophobic epidermolysis, conditions leading to inflammatory responses, osteopenias mediated by MMP activity, tempero mandibular joint disease, demyelating diseases of the nervous system, tumor metastasis or degenerative cartilage loss following traumatic joint injury, and coronary thrombosis from athrosclerotic plate rupture. The present invention also provides pharmaceutical compositions and methods for treating such conditions.

Description

Suppress matrix metalloproteinase by the compound that contains ethynyl

The background of invention invention field

The present invention relates to enzyme inhibitors, more specifically, relate to the new compound or derivatives thereof that contains the diaryl acetylene base that is used to suppress matrix metalloproteinase.Correlation technique

Matrix metalloproteinase (being also referred to as matrix metal endo-protease or MMP) is a class zinc endo-protease, comprise, but be not limited to, interstitial collagenase (being also referred to as MMP-1), stromelysin (is also referred to as mucinase, transin, or MMP-3), gelatin enzyme A (being also referred to as 72kDa-gelatinase or MMP-2) and gelatinase B (being also referred to as 95kDa-gelatinase or MMP-9).These MMP comprise inoblast and chondrocyte's secretion with various kinds of cell, with the natural protease inhibitor that is called TIMP (tissue depressant of metalloprotease).

All these MMP can destroy the multiple connectivity structural constituent of joint cartilage or basement membrane.Each MMP is secreted with nonactive proenzyme, and this proenzyme must cracking in subsequent step before it can show its proteolytic activity.Except the matrix destruction, some have contained meaning (Ito, A. as activator in the body of other MMP such as MMP-1 and MMP-9 as MMP-3 certain of these MMP; Nagase, H.Arch.Biochem.Biophys.267,211-6 (1988); Ogata, Y.; Enghild, J.J.; Nagase, H., journal of biological chemistry, 267,3581-4 (1992)).Therefore, a series of proteolytic activities can be caused by excessive MMP-3.This means that specific MMP-3 inhibitor will limit the activity of those other MMP that directly do not suppressed by this class inhibitor.

Be reported that also MMP-3 can cracking and therefore make endogenous inhibitor inactivation (Winyard, the P.G. of other proteolytic enzyme such as elastoser; Zhang, Z.; Chidwich, K.; Blake, D.R.; Carrell, R.W.; Murphy, G.FEBS Lett.279,91-4 (1991)).Therefore, the MMP-3 inhibitor can influence other destructive protease activities by changing its endogenous inhibitor level.

Numerous disease all is considered to by excessive or inappropriate matrix-destructive metal proteinase activity, or by the uneven mediation of the ratio of MMP and TIMP.These diseases comprise: a) osteoarthritis (Woessner, J.F., Jr.; Selzer, M.G., journal of biological chemistry, 259,3633-8 (1984) and Phadke, K.J.Rheumatol.10,852-60 (1983)), b) rheumatoid arthritis (Mullins, D.E.; Rohrlich, S.T.Biochim.biophys.Acta 695,117-214 (1983), Woolley, D.E.; Crossley, M.J.; Evanson, M.J.Arthritis Rheum.20,1231-9 (1977), and Gravallese, E.M.; Darling, J.M.; Ladd, A.L.; Katz, J.N.; Glimcher, L.H.Arthritis Rheum.34,1076-84 (1991), c) septic arthritis (Williams, R.J., III; Smith, R.L.; Schurman, D.J.Arthritis Rheum.33,533-41 (1990)), d) metastases (Reich, R.; Thompson, E.W.; Iwamoto, Y.; Martin, G.R.; Deason, J.R; Fuller, G.C.; Miskin, R.Cancer Res.48,3307-12 (1988) and Matrisian, L.M.; Et al Proc.Natl.Acad.Sci.U.S.A..83,9413-7 (1986)), e) periodontal disease (Overall, C.M. etc., Peridontal Res.22,81-8 (1987)), f) negative film ulcer (Burns, F.R. etc., Invest.Ophthalmol.Vis.Sci.30,1569-75 (1989)), g) proteinuria (Baricos, W.H. etc. the h) crown thrombosis (Davies that causes of atherosclerotic plaque rupture, Biochem.J.254-609-12 (1988)),, M.J. etc., Proc.Natl.Acad.Sci.U.S.A.88,8154-8 (1991)), i) aneurysma arotic disease (Vine.N. etc., Clin.Sci.81,233-9 (1991)), j) Birth control (Woessner, J.F., Jr. etc., Steroids54,491-9 (1989)), k) malnutritive epidermolysis bullosa (Kronberger, A. etc., J.Invest.Dermatol.79,208-11 (1982)) and 1) the sex change cartilage loss that causes of trauma type joint injury, cause the illness of inflammatory response, by the osteopenia of the active mediation of MMP, temporomandibular joint disease, neural demyelination, or the like (Chantry, A. etc., J.Neurochem.50,688-94 (1988)).

Under the situation of joint disease, the needs of new treatment are even more important.Osteoarthritis (OA), the main disabling effects of rheumatoid arthritis (AR) and septic arthritis are the carrying out property losses of joint cartilage and near the natural joint function it.There is not medicine on the market can prevent or slow down this cartilage loss, though NSAID (NSAID) can pain management and swelling.The net result of these diseases is thorough forfeitures of function of joint, and this can only be treated by joint replacement surgery.The MMP inhibitor is expected that the process that can stop or reversing cartilage loss avoids or delay surgery disturbing.

Proteolytic enzyme is key element at several stages in the process of the cancer that shifts.In this method, the proteolytic degradation of structural protein in basement membrane causes the diffusion in the tumour in first site, leave and return from this site, and away from second site morbidity.And the vasculogenesis of tumor inducing needs for tumor growth, and it is tissue engineered to depend on proteolysis.The transfection experiment of various types of proteolytic enzyme shows, matrix metalloproteinase, and especially, gelatin enzyme A and B (being respectively MMP-2 and MMP-9) play the part of important role in these processes.The overview in these fields is referring to Mullins, D.E etc., and Biochim.Biophys.Acta 695,177, and 1983; , Ray, J.M. etc., Eur.Respir.J.7,2062,1994; Birkedal-Hansen, H etc., Crit.Rev.Oral.Biol.Med.4,197,1993.

And, can show, suppress to stop growth of cancers (De Clerck by the degraded of the extracellular matrix of natural substrates inhibitors of metalloproteinase TIMP-2 (a kind of protein), Y.A etc., cancer research, 52,701-8 (1992)), and, TIMP-2 suppresses tumour-inductive vasculogenesis (Moses, M.A etc., science in experimental system, 248,1408-10 (1990)).Summary is referring to De Clerck, Y etc., Ann.N.Y.Acad.Sci.732,222,1994.Prove that also when the intraperitoneal administration, synthetic matrix metallo-proteinase inhibitor batimastat suppresses human colon tumor's growth, and in nude mouse, in positive bit model, spread (Wang etc., cancer research, 54,4726,1994) also prolong the survival (Davies that has the outer graft rat of human ovarian cancer, B etc., cancer research, 53,2087,1993).The application of these and related compound description among WO-A-9321942A2 (931111).

The claimed cancer that is used to block transfer of several parts of patents and patent application is arranged, promote tumour regression, the anticancer hyperplasia, delay or the loss of cartilage that prevention is relevant with osteoarthritis, or be used for the treatment of the inhibitors of metalloproteinase (Levy for example of other disease of pointing out above, et al., WO-A-9519965A1; Beckett, et al., WO-A-9519956A1; Beckett, et al., WO-A-9519957A1; Beckett, et al., WO-A-9519961A1; Brown, et al., WO-A-9321942A2; Crimmin, et al., WO-A-9421625A1; Dickens, et al., USP-4599361; Hughs, et al., USP-5190937; Broadhurst, et al., EP-0574758A1; Broadhurst, et al., EP-026436; With Myers et al., EP-0520573A1).The preferred compound of these patents has peptide backbone, at one end has zinc dentate (hydroxamic acid, mercaptan, carboxylic acid or phospho acid) and many side chains, and find at natural amino acid with the functional group that upgrades.The little peptide of this class usually is difficult for absorbing, and shows low oral bioavailability rate.They also carry out quick proteolysis metabolism, have very short half life.As an example, batimastat, at Brown, et al., the compound of describing among the WO-A-9321942A2 can only the intraperitoneal administration.

Some 3-biphenyl acyl group propionic acid and 4-dibenzyl acyl group butyric acid are described to anti-inflammatory, anti-platelet aggregation, anti-inflammatory, anti-hyperplasia, hypolipemia, rheumatism, pain relieving and hypocholesteremic medicament in the literature.These example nones are to produce MMP to suppress as the mechanism of the result of treatment that requires.Some related compound also is used as intermediate when the preparation liquid crystal.

Particularly, Tomcufcik, et al., United States Patent (USP) 3784701 have required the benzoyl propionic acid treatment inflammation and the pain of some replacement.These compounds comprise 3-biphenyl acyl group propionic acid (being Naponol) as follows.

Medicine Naponol (Fenbufen)

Child, et al., J.Pharm.Sci.66,466,1977 have described the structure activity relationship of several Naponol analogues.These comprise several such compounds, and wherein the cyclohexyl biphenyl system is substituted, or propionic acid part is by phenyl, halogen, and hydroxyl or methyl substituted, or carboxylic acid or carbonyl functional group are converted into various derivatives.Do not have to describe contain 4 '-xenyl that replaces and the propionic acid of replacement partly be combined in a compound in the molecule.The compound that phenyl as follows (compounds X L IX and L XX VII) and methyl (compounds X L VII) replace is described to inactive.

Kameo, et al., Chem.Pharm.Bull., 36,2050,1988 and Tomizawa, et al., JP-62132825A2 have described the 3-dibenzoyl phenylpropionic acid derivatives of some replacement and it comprises following analogue.Described variously being partly with other substituent compounds, but they do not contain the xenyl residue at propionic acid. X=H wherein, 4 '-Br, 4 '-Cl, 4 '-CH ₃, or 2 '-Br.

Cousse, et al., Eur.J.Med.Chem., 22,45,1987 described 3-biphenyl acyl group-propionic acid that following methyl and methylene radical replace and-vinylformic acid.Carbonyl has also been described wherein by CH ₂OH or CH ₂Displaced respective compound. X=H wherein, Cl, Br, CH ₃O, F, or NH ₂

Nichl, et al., German Patent 1957750 have also described the dibenzoyl base propionic acid that some above-mentioned methylene radical replaces.

EI-Hashash, et al., Revue Roum.Chim.23,1581,1978 have described from β-aroyl-acrylic acid epoxy thing deutero-product, comprise following biphenyl compounds.Be not described in the substituted compound of xenyl part.

Kitamura, et al., JP-60209539 have described some and have comprised the following intermediate that is used to produce liquid crystal.In the mesosome, xenyl is not substituted in these. R wherein ¹It is the alkyl of 1-10 carbon atom.

Thyes, et al., the following compound of German Patent 2854475 usefulness is made intermediate.Xenyl is not substituted.

Sammour, et al., Egypt J.Chem.151,311,1972 and Couquelet, et al., Bull.Soc.Chim.Fr.9,3196,1971 have described some comprises the biphenyl acyl group propionic acid that following dialkyl amido replaces.In all cases, xenyl all is not substituted.

R wherein ¹, R ²=alkyl, benzyl, H, or with nitrogen-atoms, morpholinyl.

Other disclose a series of carboxylic acid that contains xenyl, and its example is shown in as follows, and their suppress neural endopeptidase (NEP24.11), a kind of membrane-bound zinc metalloprotein enzyme (Stanton, et al., Bioor.Med.Chem.Lett.4,539,1994; Lombaert, et al., Bioor.Med.Chem.Lett.4,2715,1994; Lombaert, et al., Bioor.Med.Chem.Lett.5,145,1995; Lombaert, et al., Bioor.Med.Chem.Lett.5,151,1995).

Be reported that by the illustrational N-carboxyalkyl derivative that contains the xenyl ethyl glycine of compound as follows be stromelysin-1 (MMP-3), and 72kDa gelatinase (MMP-2) and Collagenase (Durette, et al., WO-9529689).

Have improved bioavailability and biological stability with respect to prior art based on the compound of peptide, and the effective MMP inhibitor that can be used for anti-specific target MMP best will be needs.This compounds is the application's a theme.

Effectively the exploitation of MMP inhibitor will provide for because MMP is active exists, or the disease of the active mediation of excessive MMP, comprise osteoarthritis, rheumatoid arthritis, septic arthritis, metastases, periodontal disease, keratohelcosis, albuminuretic methods of treatment.Several MMP inhibitor are described in the literature, comprise mercaptan (beszant, et al., J.Med.Chem.36,4030,1993), hydroxamic acid (Wahl, et al., Bioor.Med.Chem.Lett.5,349,1995; Conway, et al., J.Exp.Med.182,449,1995; Porter, et al., Bioor.Med.Chem.Lett.4,2741,1994; Tomczuk, et al., Bioor.Med.Chem.Lett.5,343,1995; Castelhano, et al., Bioor.Med.Chem.Lett.5,1415,1995), phosphoric acid (Bird, et al., J.Med.Chem.37,158,1994; Morphy, et al., Bioor.Med.Chem.Lett.4,2747,1994; Kortylewicz, et al., J.Med.Chem.33,263,1990) and carboxylic acid (Chapman, et al., J.Med.Chem.36,4293; Brown, et al., J.Med.Chem.37,674,1994; Morphy, et al., Bioor.Med.Chem.Lett.4,2747,1994; Stack, et al., Arch.Biochem.Biophys.287,240,1991; Ye, et al., J.Med.Chem.37,206,1994; Grobelny, et al., Biochemistry 24,6145, and 1985; Mookhtiar, etal., Biochemistry27,4299,1988).Yet these inhibitor generally all contain peptide backbone, absorb owing to it is low to show low oral biological activity and because quick proteolysis demonstration short-half-life.Therefore, need improved MMP inhibitor.

The invention summary

The invention provides compound with matrix metalloproteinase inhibitory activity.These compounds can be used for suppressing matrix metalloproteinase, therefore, and the anti-disease that causes by MMP.So the present invention also provides the method for pharmaceutical composition and these illnesss of treatment.

Described compound relates to the mammiferous method of treatment, comprises the compound of the present invention that Mammals is given the matrix metalloproteinase amount of suppression, and it is enough to: (a) alleviate osteoarthritis, rheumatoid arthritis, septic arthritis, periodontal disease, keratohelcosis, proteinuria, aneurysmal arotic disease, malnutritive epidermolysis blister causes the illness of inflammatory reaction, by the osteopenia of the active mediation of MMP, temporomandibular joint bone and joint diseases, or neural demyelination;

(b) cartilage of the retardance of the metastases that causes of wound type joint injury or sex change loss;

(c) reduce the Coronary thrombosis that causes by atherosclerotic plaque rupture; Or

(d) be used for Birth control.

The compounds of this invention is also as the scientific research instrument of research matrix metalloproteinase function and mechanism of in the system in vitro and in vivo.Because it is active that its MMP-suppresses, The compounds of this invention is used to regulate MMP effect, thus make the investigator can observational study in the active effect of MMP of reduction in the test organism system.

The present invention relates to have the compound of matrix metalloproteinase inhibitory activity and following general formula:

(T) _xA-B-D-E-G???(L)

In above-mentioned general formula (L), (T) _xA represents to replace or unsubstituted fragrant 6-person encircles or contain 1-2 N, O, or assorted fragrant 5-6 person's ring of S atom.T represents the acetylene series part that replaces.

In general formula (L), B represents fragrant 6-person's ring or contains 1-2 to be selected from N, O, or assorted fragrant 5-6 person's ring of S atom.Be called B ring or B unit.When N is used at B ring during with S or O associating, these heteroatomss by at least one carbon atom separately.

In general formula (L), D represents

In general formula (L), the E representative has substituent R ⁶The chain of n carbon atom, R wherein ⁶Base is an independent substituent, or constitutes spiral or non-helical ring.Ring can form in two ways: a) two R ⁶Base links to each other, and connection is with these two R ⁶The chain atom that base adheres to, and any intermediate chain atom constitute 3-7 person's ring, or b) R ⁶Base connects its R ⁶The chain that stops, connection is with this R ⁶The chain atom that base adheres to, and any intermediate chain atom constitute 3-7 person's ring.The number of carbon atom n is 2 or 3, and R ⁶The number of substituting group m is the integer of 1-3.All R ⁶The carbon number of base is at least 2.

Each R ⁶Be alkyl, alkenyl, alkynyl, heteroaryl, non-aromatic ring, and combination, it randomly replaces with one or more heteroatomss that hereinafter describe in detail.In general formula (L), E is single or two loop sections that replace, and it is optional with one or more heteroatomss replacements.

In general formula (L), G representative-PO ₃H ₂,-M,

Wherein M represents-CO ₂H ,-CON (R ¹¹) ₂Or-CO ₂R ¹², R ¹³Arbitrary side chain of 19 kinds of non-annularity natural amino acids of expression.

Most preferred compound of the present invention is:

R wherein ¹⁵Be to be selected from: HOCH ₂, MeOCH ₂, (n-Pr) ₂NCH ₂, CH ₃CO ₂CH ₂, EtOCO ₂CH ₂, HO (CH ₂) ₂, CH ₃CO ₂(CH ₂) ₂, HO ₂C (CH ₂) ₂, OHC (CH ₂) ₃, HO (CH ₂) ₄Ph, 3-HO-Ph, and PhCH ₂OCH ₂And R ¹⁶Be

Or

The pharmaceutical salts of these compounds also within the scope of the invention.

In the maximally related reference compound of prior art, the xenyl of molecule partly is unsubstituted, and propionic acid or butyric acid part or be unsubstituted, or have a methyl or phenyl.The existence that is reported that big phenyl causes that the prior art compound is as the anti-inflammation analgesic inactivation.Referring to, for example, Child, et al., Pharm.Sci.66,466,1977.On the contrary, have now found that, show that very strong MMP suppresses the substituting group that active compound partly contains considerable size at the propionic acid or the butyric acid of molecule.The xenyl of best MMP inhibitor part also preferably 4 '-position contains substituting group, when propionic acid or butyric acid part were most desirably replaced, unsubstituted biphenyl group compound of the present invention had enough activity, is considered the surrogate of practical medicine.

Some aspect of the present invention has only been summarized in the front, and does not limit the present invention in all senses.All patents of quoting in specification sheets and other publications are all drawn in full and are done this paper reference.

The explanation of preferred version

More specifically, compound of the present invention has matrix metalloproteinase inhibitory activity and following general formula:

(T) _xA-B-D-E-G (L) is (T) wherein _xA represents to be selected from following replacement or unsubstituted fragrance or assorted aromatic portion:

R wherein ¹Expression H or 1-3 carbon alkyl.

In the whole application, in the chemical structure that shows, open key refers to the point that structure is connected with other groups.For example, R wherein ⁵⁰Be Compound be following structure

In these structures, aromatic nucleus is called A ring or A unit, and each T represents substituting group, is called T group or T unit.T is the acetylene series part that replaces, and x is 1.

The B ring of general formula (L) is to replace or unsubstituted fragrance or assorted aromatic nucleus, and wherein any substituting group all is that the avtive spot of molecule and target enzyme is unworthy of, or destroys A and B ring relative configuration, if will be deleterious like that.This class group can be such as low alkyl group, lower alkoxy, CN, NO ₂, halogen, or the like part, but be not limited to this class group.

In general formula (L), B represents to be selected from following fragrance or assorted aromatic nucleus:

R wherein ¹As above definition.These rings are called as B ring or B unit.

In general formula (L), D represents part:

In general formula (L), the E representative has m substituent R ⁶The chain of n carbon atom, R wherein ⁶Be independent substituent, or constitute spiral or non-helical ring.Ring can form in two ways: a) two R ⁶In conjunction with, and together with these two R ⁶The accompanying chain atom of base, and any intermediate chain atomic building 3-7 person ring, or b) R ⁶Base is attached on the chain of its stop, and together with this R ⁶The chain atom that base adheres to, and any intermediate chain atomic building 3-7 person ring.Carbonatoms n in the chain is 2 or 3, and R ⁶Substituent number m is the integer of 1-3.At whole R ⁶Carbonatoms in the base is at least 2.

Each R ⁶Be independently selected from following 1)-14) listed substituting group in the money:

1) 1-10 carbon alkyl; Condition is, is phenyl as if the A unit, and the B unit is a phenylene, and m is 1, and n is 2, and alkyl is positioned at respect on the unitary α carbon of D, and then x is 1 or 2;

2) 6-10 carbon aryl; Condition is, is phenyl as if the A unit, and the B unit is a phenylene, and aryl is a phenyl, and n is 2, and m is 1 or 2, and then x is 1 or 2;

3) contain 4-9 carbon and have a N at least, the heteroatomic heteroaryl of O or S;

4) aralkyl, wherein aryl moiety contains 6-10 carbon and moieties contains 1-8 carbon;

5) heteroaryl-alkyl, heteroaryl wherein contain 4-9 carbon and at least one N, O, or S heteroatoms, and moieties contains 1-8 carbon;

6) alkenyl of 2-10 carbon;

7) aryl-alkenyl, aryl moiety wherein contain 6-10 carbon, and alkenyl partly contains 2-5 carbon;

8) heteroaryl-alkenyl, heteroaryl moieties wherein contain 4-9 carbon and at least one N, O, or S heteroatoms, and this alkene partly contains 2-5 carbon;

9) alkynyl of 2-10 carbon;

10) aryl-alkynyl, aryl moiety wherein contain 6-10 carbon, and alkynyl partly contains 2-5 carbon;

11) heteroaryl-alkynyl, wherein heteroaryl moieties contains 4-9 carbon and at least one N, O, or S heteroatoms, and alkynyl partly contains 2-5 carbon;

12)-(CH ₂) _tR ⁷, t wherein is 0 or the integer of 1-5, and R ⁷Be selected from

And corresponding heteroaryl moieties, the R that contains aryl wherein ⁷Aryl moiety contain 4-9 carbon and at least one N, O, or S heteroatoms.At this R ⁷In the base, Y represents O or S, R ¹, R ²And R ³As above definition, and μ=0,1 or 2, condition is to work as R ⁷Be

When the A unit was phenyl, the B unit was a phenylene, and m is 1, and n is 2, and t is 0, and x is 1 or 2.

13)-(CH ₂) _vZR ⁸, wherein v is the integer of 1-4, Z representative-S-, and-S (O)-,-SO ₂-, or-O-, and R ⁸Be selected from the alkyl of 1-12 carbon; The aryl of 6-10 carbon; Contain 4-9 carbon and at least one N, the heteroatomic heteroaryl of O or S; Aryl moiety wherein contains 6-12 carbon and moieties contains the aralkyl of 1-4 carbon; Aryl moiety wherein contains 6-12 carbon and at least one N, and O or S heteroatoms and moieties contain the heteroarylalkyl of 1-4 carbon;-C (O) R ⁹, R wherein ⁹Represent the alkyl of 2-6 carbon, the aryl of 6-10 carbon contains 4-9 carbon and at least one N, the heteroatomic heteroaryl of O or S; And aryl moiety wherein contains 6-10 carbon or contains 4-9 carbon and at least one N, O or S heteroatoms, and moieties contains the aralkyl of 1-4 carbon, condition is to work as R ⁸Be-C (O) R ⁹, Z is-S-or-O-; When Z is-O-R ⁸Also be-(C _qH _2qO) _rR ⁵, q wherein, r or R ⁵As above definition; And when the A unit is a phenyl, this B unit is a phenylene, and m is 1, and n is 2, and v is 0, and then x is 1 or 2.

14)-(CH ₂) _wSiR ¹⁰ ₃, wherein W is the integer of 1-3, and R ¹⁰Represent the alkyl of 1-2 carbon.

In addition, any T or R ⁶The aryl of base or heteroaryl moieties can be chosen wantonly and have nearly two and be selected from following substituting group :-(CH ₂) _yC (R ¹¹) (R ¹²) OH ,-(CH ₂) _yOR ¹¹,-(CH ₂) _ySR ¹¹,-(CH ₂) _yS (O) R ¹¹,-(CH ₂) _yS (O) ₂R ¹¹,-(CH ₂) _ySO ₂N (R ¹¹) ₂,-(CH ₂) _yN (R ¹¹) ₂,-(CH ₂) _yN (R ¹¹) COR ¹²,-OC (R ¹¹) ₂O-, two Sauerstoffatoms wherein all are attached to aromatic ring ,-(CH ₂) _yCOR ¹¹,-(CH ₂) _yCON (R ¹¹) ₂,-(CH ₂) _yCO ₂R ¹¹,-(CH ₂) _yOCOR ¹¹,-halogen ,-CHO ,-CF ₃,-NO ₂,-CN and-R ¹², wherein y is 0-4; R ¹¹Represent the alkyl of a H or 1-4 carbon; And R ¹²Represent the alkyl of 1-4 carbon.

In general formula (L), G represents-PO ₃H ₂,-M,

Wherein M represents-CO ₂H ,-CON (R ¹¹) ₂, or-CO ₂R ¹², R ¹³Any side chain of 19 kinds of non-annularity natural amino acids of expression.

The pharmaceutical salts of these compounds also within the scope of the invention.

It on the E unit is on the carbon of β to the D unit that the G unit most preferably is attached to, and carboxylic acid group preferably.

Should be appreciated that term used herein " alkyl " refers to straight chain, side chain, ring-type and encircle thing more.The alkyl of term " haloalkyl " finger branch or perhalogeno, for example-(CH ₂) ₂Cl ,-CF ₃And C ₆H ₁₃

In one of these schemes, the present invention relates to wherein at least one unit A, B, and R ⁶General formula (L) compound that comprises assorted aromatic nucleus.The compound that preferably contains assorted aromatic nucleus is that wherein heteroaryl is a 4-9 carbon, comprises and contains O, S, or NR ¹(when ring is 5-person), and the assorted aromatic nucleus of the 5-6 person of N (when said ring is 6-person).The particularly preferred compound that contains assorted aromatic nucleus is the compound that one of A and B unit comprise thiphene ring.When the A unit was thiophene, it preferably 2 was connected with the B unit in the position, and 5 had a substituting group T in the position.When the B unit was thiophene, it preferably was connected with the A unit with D with 5 by position 2 respectively.

In general formula (L), A and B ring preferably is respectively phenyl and phenylene, and the A ring preferably has at least one substituting group T, is preferably located in A ring and B and encircles the farthest, position that links to each other, and the D unit is carbonyl preferably, and G unit carboxyl preferably.

In another embodiment, the present invention relates to the compound of general formula (L), in the E unit, n is 2 and m is 1.Therefore these compounds have two carbon atoms between D unit and G unit, and have a substituting group on this two carbochain.

In its another embodiment, the present invention relates to the compound of general formula (L), A ring wherein is a phenyl that replace or non-replacement, and the B ring is right-phenylene, and any R that contains aryl ⁶Only contain carbon in the ring of the aryl moiety of part.These compounds thereby do not contain aromatic nucleus.

In its another embodiment, the present invention relates to the compound of general formula (L), m wherein is 1 and R ⁶It is independent substituent.These compounds are such materials, promptly only contain single substituent R on its E unit ⁶, and this substituting group is not comprised in the ring.Preferred compound has formula in this subgroup: Wherein x is 1 and substituting group T is positioned on the A ring the 4th with respect to A and B loops chalaza.The para-orienting group T of this subgroup more preferably is the part that contains ethynyl, is selected from: MeOCH ₂C ≡ C-, (n-Pr) ₂NCH ₂C ≡ C-, CH ₃CO ₂CH ₂C ≡ C-, EtOCO ₂CH ₂C ≡ C-, HOCH ₂C ≡ C-, HO (CH ₂) ₂C ≡ C-, CH ₂CO ₂(CH ₂) ₂C ≡ C-, HO ₂C (CH ₂) ₂C ≡ C-, OHC (CH ₂) ₃C ≡ C-, HO (CH ₂) ₄C ≡ C-, PhC ≡ C-, 3-HO-PhC ≡ Cand PhCH ₂OCH ₂C ≡ C-.

R wherein ⁶Be-(CH ₂) _tR ⁷Other compound of general formula (L) in t be the integer of 1-5.R wherein ⁶Be-(CH ₂) _vZR ⁸The v of preferred general formula (L) compound be the integer of 1-4 and Z for-S-or-O-.Other R ⁶For its alkyl of compound of the general formula (L) of alkyl contains 4 or more a plurality of carbon, and those R wherein ⁶The moieties at said aralkyl that is aralkyl contains 2-3 carbon.

In its another embodiment, the present invention relates to the compound of general formula (L), wherein the number of the substituting group m on the E unit is 2 or 3; And when m is 2, two R ⁶Be independent substituent, or constitute a kind of spiral ring jointly, perhaps a R ⁶Base is that independent substituent and another constitute spiral ring; And when m is 3, two R ⁶Base is independent substituent and a R ⁶Base constitutes ring, perhaps two R ⁶Base constitutes ring and a R ⁶Base is an independent substituent, or three R ⁶Be that base is an independent substituent.Therefore, this minor structure comprises such compound, and promptly E unit wherein is two or trisubstituted, and under dibasic situation, any by one or two R ⁶The ring that base forms is a spiral ring, and under trisubstituted situation, this R ⁶Base can form spiral or non-helical ring.

In its another embodiment, the present invention relates to the compound of general formula (L), wherein the number of substituting group m is 1 or 2 on the E unit; And when m is 1, R ⁶Base constitutes non-helical ring; And when m is 2, two R ⁶The common non-helical ring of formation or a R ⁶It is independent substituent and another constitutes non-helical ring.Thereby this minor structure comprises such compound, and promptly E unit wherein has one or two R ⁶Substituting group, and at least one substituting group is included in the non-helical ring.

More specifically, the representative compounds of general formula (L), wherein one or more R ⁶Substituting group relates to the form of non-helical ring, has the E unit of following structural.

Wherein a is 0,1, or 2; B is 0 or 1; C is 0 or 1; D is 0 or 1; C+d is 0 or 1; E is 1-5; F is 1-4; G is 3-5; H is 2-4; I is 0-4; J is 0-3; K is 0-2; R ⁶Sum be 0,1, or 2; U represents O, S or NR ¹And z is 1 or 2; Arbitrary R ¹⁴It is independently to be selected from: the alkyl of 1-9 carbon; Wherein moieties contains 1-7 carbon and aryl moiety contains the aralkyl of 6-10 carbon; The alkenyl of 2-9 carbon; Wherein alkenyl partly contains 2-4 carbon and aryl moiety contains the alkenyl that the aryl of 6-10 carbon replaces; The alkynyl of 2-9 carbon; Wherein alkynyl contains 2-4 carbon and aryl moiety contains the alkynyl that the aryl of 6-10 carbon replaces; The aryl of 6-10 carbon;-COR ²-CO ₂R ³-CON (R ₂) ₂-(CH ₂) _tR ⁷, wherein t is 0 or the integer of 1-4; With-(CH ₂) _vZR ⁸, wherein v is 0 or the integer of 1-3, Z representative-S-or-O-.R ¹, R ⁷And R ⁸As above definition.

The compound of preferred general formula (L), one or more R ⁶Substituting group relates to the formation of non-helical ring, and the E unit of following array structure is arranged:

A wherein, b, c, d, (c+d), e, g, i, k, R ⁶Sum, U, and R ¹⁴As above definition.

Substituting group T is preferably the part that contains ethynyl, has general formula:

R ¹⁰(CH ₂) _nC ≡ C-wherein n is 1-4, and R ³⁰Be selected from: HO, MeO-, (n-Pr) ₂N-, CH ₃CO ₂-, CH ₃CH ₂OCO ₂-, HO ₂C-, OHC-, Ph-, 3-HO-Ph-and PhCH ₂O-, condition is to work as R ³⁰When being Ph or 3-HO-Ph, n=0.

Most preferably, T is: MeOCH ₂C ≡ C-, (n-Pr) ₂NCH ₂C ≡ C-, CH ₃CO ₂CH ₂C ≡ C-, EtOCO ₂CH ₂C ≡ C-, HOCH ₂C ≡ C-, HO (CH ₂) ₂C ≡ C-, CH ₂CO ₂(CH ₂) ₂C ≡ C-, HO ₂C (CH ₂) ₂C-≡ C-, OHC (CH ₂) ₃C ≡ C-, HO (CH ₂) ₄C ≡ C-, PhC ≡ C-, 3-HO-PhC ≡ C-, and PhCH ₂OCH ₂C ≡ C-.

The subscript x of definition of T substituting group number preferably 1 or 2, most preferably be 1, and when x was 1, T are preferably located in 4 on the A ring.

A encircles preferably phenyl or thiphene ring, most preferably is phenyl.

B ring preferably 1,4-phenylene or 2, the 5-thiphene ring most preferably is 1, the 4-phenylene.

The D unit most preferably is a carbonyl.

In the E base, R ⁶Preferably:

1) aralkyl, aryl moiety wherein contain 6-10 carbon and moieties contains 1-8 carbon;

2)-(CH ₂) _tR ⁷, t wherein is 0 or the integer of 1-5, and R ⁷It is the imino-that contains aromatic residues; Or

3)-(CH ₂) _vZR ⁸, v wherein is 0 or the integer of 1-4, Z is S or O, and R ⁸Be that the aryl of 6-10 carbon or aryl moiety wherein contain 6-12 carbon and moieties contains the aralkyl of 1-4 carbon.

R ⁶Base is most preferably as follows, and any aromatic portion wherein preferably replaces:

1) aryl moiety wherein is a phenyl and moieties contains the aralkyl of 1-4 carbon;

2)-(CH ₂) _tR ⁷, t wherein is the integer of 1-3, and R ⁷Be N-(1,2-naphthalene-dicarboxyl imino-), N-(2,3-naphthalene-dicarboxyl imino-), or N-(1,8-naphthalene-dicarboxyl imino-); Or N-phthalyl imino-,

3)-(CH ₂) _vZR ⁸, v wherein is the integer of 1-3, Z is S, and R ⁸It is phenyl.

The compound of preferred general formula (L) has the R of following formula ⁶The unit:

These professional those skilled in the art will recognize that many The compounds of this invention exist enantiomorph or diastereomer form, and know in this area, and this class stereoisomeric forms in any ratio shows different activity usually in living things system.The present invention includes MMP had and suppress active all possible steric isomer, irrelevant with its stereoisomerism design, and wherein at least one has the mixture that suppresses active steric isomer.

Most preferred of the present invention is pointed out below and is named:

I) R/S 4 '-(3-hydroxyl-1-propine)-γ-oxo-α-(3-phenyl propyl)-[1,1 '-phenylbenzene]-4 butyric acid,

II) S-4 '-(3-hydroxyl-1-propine)-γ-oxo-α-(3-phenyl propyl)-[1,1 '-phenylbenzene]-4 butyric acid,

III) R-4 '-(3-hydroxyl-1-propine)-γ-oxo-α-(3-phenyl propyl)-[1,1 '-phenylbenzene]-4 butyric acid,

IV) 4 '-(3-methoxyl group-1-propine)-γ-oxo-α-(3-phenyl propyl)-[1,1 '-phenylbenzene]-4 butyric acid,

V) γ-oxo-α-(3-phenyl propyl)-4 '-(3-propyl group-1-hexin base)-[1,1 '-phenylbenzene]-4 butyric acid,

VI) 4 '-[3-(acetyl oxygen)-1-proyl]-γ-oxo-α-(3-phenyl propyl)-[1,1 '-phenylbenzene]-4 butyric acid,

VII) 4 '-[3-(ethoxycarbonyl) oxygen]-1-proyl]-γ-oxo-α-(3-phenyl propyl)-[1,1 '-phenylbenzene]-4 butyric acid,

VIII) 4 '-(4-hydroxyl-ethyl acetylene base)-γ-oxo-α-(3-phenyl propyl)-[1,1 '-phenylbenzene]-4 butyric acid,

IX) 4 '-[3-(acetyl oxygen)-1-propine]-γ-oxo-α-(3-phenyl propyl)-[1,1 '-phenylbenzene]-4 butyric acid,

X) 4 '-(4-carbonyl-ethyl acetylene base)-γ-oxo-α-(3-phenyl propyl)-[1,1 '-phenylbenzene]-4 butyric acid,

XI) γ-oxo-4 '-(5-oxo-1-pentynyl)-α-(beta-phenyl propyl group)-[1,1 '-phenylbenzene]-4 butyric acid,

XII) 4 '-(6-hydroxyl-1-hexin base)-γ-oxo-α-(3-phenyl propyl)-[1,1 '-phenylbenzene]-4 butyric acid,

The X III) γ-oxo-4 '-(phenylacetylene base)-α-(3-phenyl propyl)-[1,1 '-phenylbenzene]-4 butyric acid and

The XI V) 4 '-[3-hydroxy phenyl]-ethynyl]-γ-oxo-α-(3-phenyl propyl)-[1,1 '-phenylbenzene]-4 butyric acid,

The X V) 1,3-dihydro-1,3-dioxo-α-[2-oxo-α-[2-oxo-2-[4 '-[3 (phenyl methoxyl group)-1-proyl] [1,1 '-phenylbenzene]-4-yl] ethyl]-2H-isoindole-2-butyric acid and

The X VI) 1,3-dihydro-α-[2-[4 '-(hydroxylated tolan base) [1,1 '-phenylbenzene]-the 4-yl]-the 2-oxoethyl]-1,3-dioxo-2H-isoindole-2-butyric acid.General preparation method:

Compound of the present invention can be by using known chemical reactions and prepared.But, following general preparation method is used to help the reader to synthesize this inhibitor, and the experimental section that is described below work embodiment has more detailed specific embodiment.If do not particularly point out below, the variable group of all of these methods is all described in general explanation.For the whole bag of tricks, variable subscript n defines independently.When the variable group that has the symbol that provides (is R ⁹) when in the structure that provides, repeatedly using, should be appreciated that each of these groups can change independently in the scope for this symbol definition.

It is respectively that the The compounds of this invention of the phenyl that replaces and phenylene is by with the biphenyl M II that replaces and contain activated intermediate such as Succinic anhydried or the Pyroglutaric acid derivative M III or the acyl chlorides M IV of acyl group that general method A-wherein encircles A and B; in the presence of Lewis acid catalyst such as aluminum chloride; at aprotic solvent as 1; 1; 2, the Friedel-Crafts reaction preparation easily in the 2-tetrachloroethane.Known Friedel-Crafts reaction can be used Berliner, Org.React., and 5,229 (1949) and H.Heaney, Comp.Org.Synth., 2,733, many other solvents and acid catalyst described in 1991 are finished.

If acid anhydrides M III is to replace or polysubstituted so that asymmetric mode is single by any one acid anhydrides of two carbonyls of attack, then crude product M I-A often exists with the form of isomer mixture.The isomer that produces can be by being separated into pure form with this professional known standard method crystallization or chromatography.

In the time can not buying, Succinic anhydried M III can (cause side chain R by the Stobbe condensation of succinic acid dialkyl ester and aldehydes or ketones ⁶), then catalytic hydrogenation is hydrolyzed to diacid with half-ester intermediate, then by being converted into acid anhydrides M III with Acetyl Chloride 98Min. or acetic anhydride.In addition, half-ester intermediate is converted into acyl chlorides M IV by handling with thionyl chloride or oxalyl chloride.The summary of Stobbe condensation comprises acyl chlorides or the oxalyl chloride processing listed, is converted into acyl chlorides M IV.The summary of Stobbe condensation comprises suitable solvent and the alkali listed, referring to Johnson and Daub, Org.React., 6,1,1951.

This method is used to prepare M III (R ⁶=H, isobutyl-and H, n-pentyl),, narrated in the United States Patent (USP) 4771038 people such as Wolanin.Method A

Method A is for preparation ring compound such as M I-A-3, wherein two R ⁶Group forms 3-7 person in conjunction with methene chain and encircles particularly useful.Easy form with the cis-isomeride of generation cis The compounds of this invention M I-A-3 of little ring (3-5 member) acid anhydride obtains.Then, in THF, handle M I-A-3 such as the alkali of DBU and prepare trans-compound M I-A-4 by using.The four membered ring's raw material acid anhydride that replaces such as M III-A-1 form with photochemistry 2+2 reaction as follows.This method is for preparing wherein R ¹⁴The compound that is acetoxyl group or acetoxyl group methylene radical is particularly useful.After the Friedel-Crafts reaction, acetic ester can be removed by alkaline hydrolysis, and carboxyl is protected by being converted into 2-(trimethyl silyl) ethyl ester.The R that produces ¹⁴=CH ₂The intermediate of OH can be converted into other R by being used in the technology described in the general method G ¹⁴The compounds of this invention.

Between the C-2 and C-3 of two keys at the succinyl chain (for example, maleic anhydride or 1-cyclopentenes-1,2-dicarboxylic anhydride), or two key is on side chain the time, and the Friedel-Crafts method also is useful, as is used for itaconic anhydride and makes raw material, produces wherein R ⁶Outside group forms on a chain carbon together-methylene radical (=CH ₂) product.The subsequent applications of these compounds is narrated in method D.

General method B-in addition, compound M I can be by the preparation of such response procedures: dialkyl malonate M VI forms intermediate M VII with alkyl halide one alkylation, then with the alkylation of halogenated methyl biphenyl ketone M VIII, produces intermediate M IX.The compound of structure M IX with alkali aqueous solution hydrolysis and heating, makes propanedioic acid intermediate decarboxylation then, produces M I-B-2 (method B-1).By the alkali aqueous solution with monovalent, R ¹²Ester M I-B-2 as alkyl is obtained, and uses more than 2 normal alkali aqueous solutions, obtains acid compound (R ¹²=H).Non-imposed ground does not heat, and obtains diacid or acid-ester M I-B-1.

In addition, diester intermediate M IX can with strong acid such as concentrated hydrochloric acid in acetate, in tube sealing, about 110 ℃ of heating produced M I-B-1 (R in about 24 hours ¹²=H).In addition, be reflected at and the alkyl halide reaction of M VI and M VIII are carried out before, produce same M IX (method B-2).

In addition, contain R ¹²The diester intermediate M X IX of=alkyl can contact with the Pd catalyzer in the presence of tetramethyleneimine, produces M I-B-2 (R ¹²=H) (Dezeil, Tetrahedron Lett.28,4371,1990).

From biphenyl M II, react at Friedel-Crafts with halo acetyl halide such as bromo acetyl bromide or chloro-acetyl chloride, form intermediate M VII.In addition, biphenyl can with Acetyl Chloride 98Min. or acetic anhydride, the product usefulness of generation for example, is used the bromine halogenation, produces intermediate M VIII (X=Br).

When method A produced mixture, method B had the advantage that produces single regional isomer.As side chain R ⁶Contain fragrance or assorted aromatic nucleus, if using method A, they will participate in the intramolecularly acylation reaction, provide by product, and this moment method B is particularly useful.As the R adjacent with the carboxyl of final compound ⁶Group contains heteroatoms such as oxygen, sulphur, or nitrogen, or when more complicated functional group such as inferior acid amides ring, this method is also particularly useful.Method B

Work as R ⁶When containing the Z of functional group of selection, malonic ester M VII can prepare by the not replacement malonic ester alkylation that makes purchase with prenyl or allyl halide, make this product ozonolysis, reductibility is handled, required Z group can react (Mitsunobu by Mitsunobu, Synthesis1,1981) coupling.In addition, intermediate ethanol can provide the malonic ester M that contains required Z group VII under alkylation conditions.

General method C-is useful especially be with chirality HPLC separation of racemic mixture enantiomorph (referring to, for example, Arit, et al., Chem.Int.Ed.Engl.12,30 (1991)).The compounds of this invention can be by preparing with the form of the auxiliary approach of chirality with pure enantiomorph.Referring to, for example, Evans, Aldrichimica Acta, 15 (2), 23,1982 with the known similar reference of other these specialties.

General method D-is R wherein ⁶Be alkyl-or aryl-or heteroaryl-or acyl group-or the compound of heteroaryl carbonyl-thio-methylene by being similar to the described method preparation of patent WO90/05719.Therefore, the itaconic anhydride M X VI (n=1) of replacement is reacted under the Friedel-Crafts condition, produces sour M I-D-1, can separate with a spot of isomer M I-D-5 by chromatogram or crystallization.In addition, M I-D-5 reacts in the presence of alkali with formaldehyde by The compounds of this invention M I-D-4 (by any acquisition of method A to C) and obtains.

Compound M I-D-1 or M I-D-5 then with mercapto derivatives M X VII or M X VIII at catalyzer such as salt of wormwood, ethyl diisobutyl amine, tetrabutylammonium or free-radical initiator such as Diisopropyl azodicarboxylate (AIBN) exist down, in solvent such as diethylformamide or tetrahydrofuran (THF), react, produce The compounds of this invention M I-D-2, M I-D-3, M I-D-6 or M I-D-7.Method D

General method E-such as the application's aryl-linking compound can be a zinc by metal wherein also, tin, magnesium, lithium, boron, silicon, copper, aryl of cadmium or the like or heteroaryl metallic compound intersect with the Suzuki or the Stille of aryl or heteroaryl halogenide or triflate or the like-the coupled reaction preparation.In the equation below, one of Met or X are metals, and another is halogen or trifluoromethanesulfonic acid base (OTf).Pd (com) is that the solubility title complex of palladium is as four (triphenyl phosphine)-palladiums (O) or two (triphenyl phosphine) palladium (III) muriate.These methods are known in this specialty.Referring to, for example, Suzuki, Pure Appl.Chem.63,213 (1994); Suzuki, Pure Appl.Chem.63,419 (1991); With farina and Roth. " Metal-Organic Chemistry " Vol.5 (Chapter1), 1994.

Raw material M XX III (B=1,4-phenylene) is with being similar to method A, B, and the method for C or D, but make raw material with halogeno-benzene without biphenyl and easily form.When needing, wherein X is that the raw material of halogen can be converted into wherein that X is the compound of metal by this professional known reaction, as handling the bromo intermediate with hexa methyl ditin and four (triphenyl phosphine) palladium in reflux in toluene, produces the tin trimethyl intermediate.Raw material M XX III (B=heteroaryl) is the easiest of method C, but with the heteroaryl rather than the biphenyl feedstock production of acquisition easily.Intermediate M X XII both can be bought, and also can pass through this professional known method, easily prepared from the raw material of buying.Method E

(T) _xA-Met+X-B-E-G→(T) _xA-B-D-E-G

MⅩⅫ?MⅩⅩⅢ?Pd(com)MⅠ-E

T, x, A, B is in E and G such as the structure (L)

Met=metal, X=halogen or trifluoromethanesulfonic acid base

Or

Met=halogen or trifluoromethanesulfonic acid base, the X=metal

These general methods react for the Friedel-Crafts of preparation by various dibenzyl acidylate schemes, as method A, and B, C or D are useful with the compound that produces mixture.Method E is for preparing wherein aryl, and A or B contain the product of one or more heteroatomss (heteroaryl), as contain thiophene, furans, and pyridine, the pyrroles, oxazole, thiazole, pyrimidine or pyrazine ring etc. replace the compound of phenyl particularly useful.

General method F-is as the R of method F ⁶When forming 4-7 person's carbocyclic ring together in group such as the following intermediate M XX V, two keys can be by handling with 2 equivalent highly basic such as di-isopropyl lithamide or hexamethyl silyl lithamide or the like, then use sour cancellation, remove the conjugation with ketone, produce the compound of structure M XX VI.M XX VI and mercapto derivatives react with the method that is similar to general method D, then method F

General method G-is two R wherein ⁶Group is united the The compounds of this invention most convenient ground that forms the 5-person's ring that replaces and is prepared by method G.In this method, sour CL II (R=H) Tetrahedron 37, Suppl., 411 (1981) described schemes preparations.By with coupler such as 1-(3-dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride and present methods known in the art, the acid protection is ester [for example R=benzyl (Bn) or 2-(trimethyl silyl) ethyl (TMSE)].The bromo biphenyl C III that replaces is converted into its Grignard reagent by handling with magnesium, and produces pure C VI with the reaction of C I.Alcohol C VI is by with this professional known condition, its methanesulfonates of alkaline purification and eliminate generation alkene C VII.In addition; by bromide being metallized with n-Butyl Lithium at low temperature (78 ℃) earlier; then handle with the chlorine tin trimethyl; the C III is converted into the tin trimethyl intermediate; by in the presence of strong non-proton alkali with 2-[N; N-two (trifyl) amino]-reaction of 5-chloropyridine, the C I is converted into enol triflate (C II).Tin and enol triflate intermediate are then at Pd ⁰Catalyzer, CuI and AsPh ₃There is coupling down, directly produces intermediate C VII.C VII ozonolysis (handling with methyl-sulfide) produces aldehyde C VIII.In addition, use OsO ₄Handle, then use HIO ₄Handle, the C VII is converted into the C VIII.Method G

Crucial intermediate C VIII is finished in several modes to target patent conversion of compounds, depends on the character of side chain functionalities Z.C VIII and Witting reagent react, then hydrogenation, producing wherein, Z is the product of alkyl or aralkyl.Use reductive agent as three [(3-ethyl-3-amyl group) oxygen base] lithium aluminum hydride (LTEPA) selective reduction aldehyde C VIII, produce pure C IX.This alcohol is converted into the derivative of phenyl ether or the replacement of multiple heteroatoms, and this derivative is used to produce side chain Z through the Mitsunobu reaction with this professional known condition (referring to Mitsunobu, Synthesis, 1 (1981)).In addition, the alcohol of C IX is converted into leaving group by this professional known condition, and as tosylate (C X) or bromide, leaving group is by suitable nucleophilic reagent displacement then.Several examples of this class reaction can be at Norman et al., J.Med.Chem.37,2552 (1994) middle discoveries.The direct acidylate of alcohol C IX produces the wherein compound of Z=OAcyl, and alcohol reacts the generation alkyl oxide with various alkyl halides in the presence of alkali.In all cases, final step all is with the stability that depends on R and Z, but all be the known condition of those skilled in the art in all cases, remove acid seal and close radicals R, as removing benzyl by basic hydrolysis, or, remove 2-(trimethyl silyl) ethyl with the tetrabutylammonium processing, produce acid (R=H).

The acid amides of general method H-The compounds of this invention acid can be from acid by suitable solvent such as methylene dichloride or dimethyl formamide, with uncle or secondary amine and coupler such as dicyclohexylcarbodiimide processing and prepare.These reactions are that this specialty is known.Amine component can be that simple alkyl or aralkyl replace, and maybe can be that wherein carboxyl is closed and amino is the free amino acid derivative.

General method I-is (T) wherein _xThe The compounds of this invention that is the alkynyl of alkynyl or replacement prepares according to general method I (Austin, J.Org.Chem.46,2280 (1981)).Intermediate M X is according to method A, B, and C, D or G are from the M III (R that buys ¹=Br) begin to prepare.The acetylene M IX of M X and replacement is reacted in the presence of Cu (I)/palladium reagent, provides The compounds of this invention M I-I-1.In some cases, R ³Can be alcohol with the trialkylsilkl sealing.Under this class situation, silyl can be by removing as trifluoroacetic acid or HF-pyridine agent treated with acid.The method I

The suitable pharmaceutical salts of The compounds of this invention comprises the additive salt that forms with organic or inorganic alkali.Becoming salt ion from this class alkali deutero-can be metal ion, for example, aluminium, alkalimetal ion, as sodium or potassium, alkaline-earth metal ions such as calcium or magnesium, or amine salt ion, wherein many this purposes that become known for.Example comprises ammonium salt, aromatic yl alkyl amine such as dibenzyl amine and N, N-dibenzyl-ethylenediamin, low-grade alkylamine such as methylamine, tert-butylamine, PROCAINE HCL, PHARMA GRADE, low alkyl group piperidines such as N-ethylpiperidine, Cycloalkyl amine such as cyclo-hexylamine or dicyclohexylamine, the 1-adamantanamines, benzathine, or from amino acid such as arginine, deutero-salt such as Methionin.Physiologically acceptable salt such as sodium salt or sylvite and amino acid salts can as described belowly pharmaceutically used, and are preferred.

These and other does not need physiologically acceptable salt is useful at isolated or purified during acceptable product in following purpose.For example, in being commonly called the method for " classical split ", the amine of the enantiomer-pure that can buy can produce the single enantiomorph salt crystal of The compounds of this invention as (+)-cinchonine in suitable solvent, stay opposite enantiomorph in solution.Because the enantiomorph of a given The compounds of this invention is more much bigger than its enantiomorph on physiological action, so this active isomer can be purified with crystal or liquid phase.The sour form of this salt by compound and equivalent, the alkali reaction of alkali ion is provided in medium and produces, wherein this salt precipitates or in water-bearing media, freeze-drying then.Free acid form can from salt provide common and technology, for example, use sal enixum, hydrochloric acid or the like acquisition.

Compound of the present invention has been found and has suppressed matrix metalloproteinase MMP-3, and therefore MMP-9, and MMP-2 can be used for the treatment of or prevent relative illness.Because other MMP that does not list in the above and the very homology of listing above of high level that has especially on catalytic site, therefore, can think that compound of the present invention should also suppress other MMP of this class in varying degrees.Change the substituting group on the aryl moiety in the molecule, and the substituting group of the butyric acid chain of desired compound, the relative inhibition that can influence listed MMP proved.Therefore, the compound of this general type can pass through to select specific substituting group and " adjusting ", thereby the inhibition of the specific MMP relevant with the particular pathologies situation is reinforced, and makes MMP not to be covered few influenced.

The method of the illness of treatment matrix metalloproteinase-mediation can comprise in the human body and implementing the Mammals that suffers from this class illness.

Inhibitor of the present invention is supposed to be used for animal doctor and people.Therefore, they are used in the pharmaceutical composition, and this pharmaceutical composition contains activeconstituents and adds one or more pharmaceutically acceptable carriers, thinner, and weighting agent, tackiness agent and other vehicle depend on the dosage form of administering mode and expectation.

The administration of inhibitor can be any suitable manner known to those skilled in the art.The example of suitable administered parenterally comprises intravenously, intraarticular, subcutaneous and intramuscular approach.Intravenous administration can be used to obtain the acute adjusting of the peak plasma concentration of medicine.Improved transformation period and medicine can be strengthened by medicine is captured in the liposome the target aiming of joint cavity.By ligand being mixed the periphery that is combined in the liposome on the synovia specificity macromole, can improve the selectivity of liposome to the aiming of joint cavity target.In addition, be with or without under the situation of pharmaceutical capsuleization, intramuscular, intraarticular or subcutaneous storage are expelled to degradable microballoon, for example, comprise the microballoon of poly-(DL-rac-Lactide-co-glycollide), can be used to obtain medicament slow release.For the facility that dosage form improves, can be with the storage of i.p. implantation with at interval as Percuseal system from Pharmacia obtains.Complying with also of facility of improving and patient can be by with injection pen (for example Novo Pin or Q-pen) or dermojet (for example obtaining from Bioject or Becton Dickinson) realization.Zero-the rank that delay or other accurate sustained release discharge as pulsation also can use implantable pump as required, medicine is transported to the synovia space by sleeve pipe realizes.Its example comprises the osmotic pump that subcutaneous implantation obtains from ALZA, as the ALZET osmotic pump.

Nasal cavity carry can be by medicine being mixed biological viscosity particulate vector (＜200 μ m) as comprising Mierocrystalline cellulose, the carrier of polyacrylic ester or polycarbophil combines and realizes with suitable absorption enhancer such as phosphatide or fatty acyl carnitine.The system that can buy comprises those of DanBiosys and Scios Nova exploitation.

Opposite with the various peptide compounds of listing in the application's background parts, the outstanding contributions of The compounds of this invention are the Orally actives that The compounds of this invention shows.Some compound has demonstrated the bioavailability up to 90-98% in various animal models.Oral delivery can be by mixing tablet with medicine, coated tablet, and drageeing, hard or soft capsule, solution is in emulsion or the suspension and realize.Oral delivery also can be designed to and will realize in the casing capsule of drug release in the very low colon of digestible protein enzymic activity by medicine is mixed.Its example comprises respectively the OROS-CT/Osmet that obtains from ALZA and Scherer DrugDelivery Systems ^TMAnd PULSINCAp ^TMSystem.Other system uses the azo-cross-linked polymer by the special bacterium azo reductase degraded of colon, or the pH sensitivity, the activatory polyacrylate polymers by rising colonic pH.Said system can be united use with absorption enhancer widely.

Rectum is carried and can be realized by medicine is mixed suppository.

The compounds of this invention can be made above-mentioned preparation by adding the inorganic or organic carrier of the known various treatment inert of those skilled in the art.These examples include, but not limited to lactose, the W-Gum or derivatives thereof, and talcum, vegetables oil, wax, fat, how pure as polyoxyethylene glycol, water, sucrose, alcohols, glycerine or the like.Various sanitass, emulsifying agent, dispersion agent, seasonings, wetting agent, antioxidant, sweeting agent, tinting material, stablizer, salt, buffer reagent or the like also is added into as required, help stabilization formulations, or help to increase the bioavailability of activeconstituents, be created in the preparation that to accept taste or smell under the oral dosage form situation.

The amount of applied pharmaceutical composition will depend on recipient and the illness of being treated.Required amount does not need the over-drastic experiment, is determined by those skilled in the art.In addition, required amount can must be suppressed and the amount of sanatory target enzyme is the basis calculates to measure.

Matrix metallo-proteinase inhibitor of the present invention not only can be used for the treatment of illness discussed above, and can be used for the purifying of metalloprotease, the test of matrix metal proteinase activity.This class activity test both can be with natural or the synthetic zymin is external carries out, also can use, for example, wherein the abnormal destruction enzyme level carries out in the inductive animal model by natural discovery (with transgenation or transgenic animal) or by the administration of exogenous medicament or by the operation that destroys stability of joint.

Experiment

The following example only is used to illustrate, and does not limit the present invention in all senses.General process:

Unless otherwise indicated, all reactions all in flame-drying or baking oven-exsiccant glassware, at the argon gas direct draught, and are carried out under induction stirring.Responsive liquid and solution shift by syringe or conduit, and import in the reactor by diaphragm of rubber.Unless otherwise indicated, reaction product solution concentrates with the Buchi vaporizer.Raw material:

The reagent and the solvent of commercial grade use without being further purified, and have only ether and tetrahydrofuran (THF) to distill with the benzophenone ketyl is conventional in argon gas, and methylene dichloride distills with hydrolith in argon gas.Many special organic or metal organic raw material and reagent is from Aldrich, 1001West Saint Paul Avenue, and Milwaukee, WI53233 obtains.Solvent is obtaining from EM Science as VWR Scientific classification usually.Chromatogram:

Analyze thin-layer chromatography (TLC) at Whatman ^The glass of precoating props up on the silica gel 60AF-254 250 μ m plates that carry and carries out.The colour developing of spot is undertaken by one of following technology: (a) ultraviolet lighting, (b) be exposed in the iodine steam, (c) plate is immersed 10% ethanolic soln of phospho-molybdic acid, heating then, (d) plate is immersed 3% ethanolic soln of the four oxygen benzaldehydes contain 0.5% vitriol oil, heating, and e then) the plate immersion is contained in 5% potassium permanganate solution of 5% yellow soda ash, then heating.

Column chromatography 230-400 order EM Science ^Silica gel carries out.

Analytical high performance liquid chromatography (HPLC) is at 1mL min ^-1At 4.6 * 250mm Microsorb ^Carry out on the post, in 288nm monitoring, and partly preparation property HPLC at 24mL min ^-1At 21.4 * 250mmMicrosorb ^Carry out on the post, monitor at 288nm.Instrument:

Fusing point (mp) is measured with Thomas-Hoover fusing point instrument, and not calibrated.

Proton (1H) nucleus magnetic resonance (NMR) spectrum General Electric GN-OMEGA300 (300MHz) spectrometer measurement, carbon 13 ( ¹³C) NMR spectrum General Electric GN-OMEGA300 (75MHz) spectrometer measurement.The synthetic majority of compounds is analyzed by NMR in the experiment below, and in all cases, spectrum is consistent with the structure of hypothesis.

Mass spectrum (MS) data with liquid-caesium two generations ion (LCIMS), the version of a up-to-date fast atom bombardment (FAB), obtain on Kratos Concept 1-H spectrograph.The synthetic majority of compounds is by mass spectroscopy in the experiment below, and in all cases, spectrum is consistent with the structure of hypothesis.The general explanation:

For multistep technology, step is in succession indicated with numeral.Variation in the step is indicated with letter.Line in list data refers to tie point.Embodiment 1-prepares chemical compounds I

Step 1 is 2 liters drying, three necks, and round-bottomed flask is loaded onto stirring rod, the isobaric funnel that adds, argon gas inlet and thermometer.NaH (8.4 gram 95%NaH pack in this flask;～0.33mol) dry THF (700ml) suspension and cool off with ice-water bath.With addition funnel in 25 minutes, drip diethyl malonate (48.54g, 0.30mol).Continue to stir 1.5 hours, then in ten minutes, add 1-bromo-3-phenyl-propane (47) ml by addition funnel ,～61g ,～0.30mol).(THF, 2 * 10ml) added this reaction mixture and continuously stirring 30 minutes to the rinsing liquid of addition funnel.Replace this addition funnel and thermometer with reflux exchanger and stopper, and this reaction solution of reflux 19 hours.Cool off this mixture to room temperature, use ice-water bath then.Slowly add distilled water (400ml) while stirring.Layering, and water extracts with chloroform (100ml).With the organic phase of 10%HCl (250ml) washing merging, and isolating water is stripped with chloroform (100ml).With saturated NaHCO ₃(250ml) wash the organic phase of this merging, with chloroform (100mL) this isolating water of stripping.Dry organic phase (Na ₂SO ₄) and the concentrated yellow oil that obtains, it is by Vigreux post decompression (0.4 holder) distillation purifying.124-138 ℃ of ebullient fraction is purified required product (57.21g, 0.206mol; 68% yield).TLC (50% hexane-methylene dichloride): R _f=0.32. Step 2 is with 1 liter, and a neck round-bottomed flask is equipped with diaphragm of rubber and argon gas inlet.The 4-bromo phenylbenzene of in this flask, packing into commercially available (50.00g, methylene dichloride 0.215mol) (100ml) solution.(21.0ml, 48.7g 0.230mol) and with ice-water bath cool off this solution to 0 ℃, and add AlCl in batches to add bromoacetyl bromide with syringe ₃(34.3g, 0.258mol).Bubbing from opaque olive-green reaction mixture.After following 24 hours of the room temperature, reaction mixture is injected cold saturated NaHCO carefully ₃In the aqueous solution.With the mixed solution of the ethyl acetate extraction gained of every part of 200ml three times, and with the organic layer Na that merges ₂SO ₄Drying, the concentrated required product that obtains the yellow solid of quantitative yield.TLC (30% ethylene dichloride-hexane), R _f=0.30 Step 3 is with 2 liters of exsiccant, and three necks, round-bottomed flask are adorned with magnetic stirring bar, argon gas inlet and isobaric addition funnel.In this bottle, charge into product (63.0g, THF 0.227mol) (500ml) solution of step 1.Use the ice-water bath reactor vessel cooled, slowly add simultaneously in batches NaH (5.40g, 95%NaH, 0.214mmol).0 ℃ was stirred this reaction mixture 1 hour down, and added product (80.0g, anhydrous THF (300ml) solution 0.215mol) of step 2 in about 20 minutes time by addition funnel.At room temperature in the atmosphere of argon gas, stir the reaction mixture 3 hours of this darkorange.This reaction vessel of cooling in ice-water bath, and the careful simultaneously distilled water (150ml) that adds.With this water of ethyl acetate extraction of each 300ml three times, use MgSO ₄The dry organic phase that should merge, and the concentrated 124g darkorange oil that obtains.This material need not purifying and is used for next-step operation.

Orange oil is dissolved in 1: 1 THF of 400ml: in the methyl alcohol, and add the NaOH aqueous solution (4N, 500ml, 2.00mol) in.This reaction mixture was at room temperature stirred 24 hours, 50 ℃ following 48 hours, and following 24 hours of room temperature.Vacuum is removed most of MeOH and is used 1: 1 ethyl acetate of 200ml part: this residue of hexane extraction of hexane and 200ml part.With this water of HCl acidifying, with the ethyl acetate extraction of 2 * 200ml part and 3 * 100ml part.MgSO ₄The organic phase of dry this merging also concentrates the diacid that obtains quantitative yield.TLC (10% methyl alcohol-chloroform contains 1% acetate): R _f=0.45

Step 4 is dissolved in 1 with the unpurified diacid of step 3, and 4-diox (500ml) also is heated to backflow 24 hours.Solvent removed in vacuo goes up chromatogram with 10g part residue at silica gel (the 10-50% ethyl acetate-hexane gradient wash-out that contains 1% acetate) and obtains the required yellow solid product of 0.840g (10%).MP174℃。 Step 5 is with a neck, and 15ml, round-bottomed flask adorn with diaphragm of rubber and argon gas inlet, and fill diethylamine with 2.6ml, the product of step 4 (0.300g, 0.667mmol), propargyl alcohol (1.0ml, 0.96g, 17mmol), and copper(I) iodide (7) (0.0220g, 0.115mmol), with two (triphenylphosphine) palladiums of trans-dichloro (0.110g, 0.157mmol).At room temperature stir the mixture 4 days of gained.Concentrated reaction mixture (290mg residue) also obtains coupled product white solid (0.035g, 40%) at 50g silica gel (20% ethyl acetate-hexane contains 0.5% acetate) upper prop chromatogram purification part residue (90mg).MP130℃。The preparation of embodiment 2 and embodiment 3-compound ii and III

At Chiralcel AD ^2.(2cm * 25cm) goes up and uses 5%EtOH, 4.75%H post ₂The CH of O and 0.095%HOAc ₃CN solution, the product by chiral separation embodiment 1 prepared embodiment 2 and 3 in flow velocity 20ml/ minute.Embodiment 2 is at first from Chiralcel AD ^2.Wash-out on the post:

¹H NMR (300MHz, CDCl ₃) δ 8.02 (d, J=8.4Hz, 2H), 7.67 (d, J=8.7Hz, 2H), 7.58 (d, J=8.7Hz, 2H), 7.53 (d, J=8.4Hz, 2H), 7.17-7.33 (m, 5H), 4.54 (s, 2H), 3.46 (dd, J=8.1,16.8Hz, lH), and 3.14-3.02 (m, 2H), 2.65 (t, J=7.2Hz, 2H), 1.64-1.84 (m, 4H). embodiment 3 is then from Chiralcel AD ^2.Wash-out on the post:

¹H NMR (300MHz, CDCl ₃) δ 8.02 (d.J=8.4Hz, 2H), 7.67 (d, J=8.7Hz, 2H), 7.58 (d, J=8.7Hz, 2H), 7.53 (d, J=8.4Hz, 2H), 7.17-7.33 (m, 5H), 4.54 (s, 2H), 3.46 (dd, J=8.1,16.8Hz, 1H), 3.14-3.02 (m, 2H), 2,65 (t, J=7.2Hz, 2H), 1.64-1.84 (m, 4H). embodiment 6-prepares the compound VI

To be furnished with a neck of diaphragm of rubber and argon gas pin inlet, 10ml, round-bottomed flask charge into the 0.5ml pyridine, embodiment 1 product (0.0070g, 0.014mmol), and diacetyl oxide (0.020ml, 22mg, 0.21mmol).Stir this reaction mixture 2 hours under the room temperature, and join 30ml 1NHCl.With the resulting mixture of 3 * 30ml ethyl acetate extraction, MgSO ₄The dry organic phase that merges also concentrates.Obtain the compound of 3mg (38%) embodiment 6 by HPLC (2.5% ethyl acetate-methylene dichloride contains 0.1% trifluoroacetic acid) purifying.MP137℃。Embodiment 7-prepares the compound VII

To be furnished with a neck of diaphragm of rubber and argon gas pin inlet, 15ml, round-bottomed flask charge into the 2ml triethylamine, 2ml THF, chemical compounds I (0.0570g, 0.134mmol), and Vinyl chloroformate (0.032ml, 36mg, 0.34mmol).Stir this reaction mixture 16 hours under the room temperature and be added among the 50ml 1NHCl.With the mixture of the ethyl acetate extraction gained of 3 * 50ml, with the organic phase MgSO that merges ₄Dry and concentrated.Go up column chromatography at 10g silica gel (40% ethyl acetate-hexane contains 0.5%HOAc), obtain 1mg (1.5%) embodiment 7 compounds by HPLC (1.5% ethyl acetate-methylene dichloride contains 0.01% trifluoroacetic acid) purifying subsequently.MS(FAB-LSIMS)499[M+H] ⁺。Embodiment 11-prepares the compound XI

The neck that to be furnished with diaphragm of rubber and argon gas pin inlet, 25ml, round-bottomed flask charges into 1mlCH ₂Cl ₂, embodiment 12 compounds (0.012g, 0.026mmol) and press Dess etc., the organic chemistry magazine, the Dess-Martin reagent of 48,4156,1983 preparations (16mg, 0.038mmol).In 0 ℃ of mixture that stirs down this gained 30 minutes,, and wash with 2 * 20ml 1NHCl with the dilution of 30ml ethyl acetate.With organic layer MgSO ₄Drying, and concentrate.Obtain 1mg (9%) embodiment 11 compounds by HPLC purifying (1.5% ethyl acetate-methylene dichloride contains 0.01% trifluoroacetic acid).

¹H?NMR(300MHz,CDCl ₃)δ9.70(t,J=1.3Hz,1H),8.05(d,J=8.4Hz,2H),7.70(d,J=8.4Hz,2H),7.65(d,J=8.4Hz,2H),7.44(d,J=8.4Hz,2H),7.15-7.35(m,5H),3.46(dd,J=8.1,16.8Hz,1H),3.14-3.02(m,2H),2.67(t,J=7.2Hz,2H),2.48(t,J=7.5Hz,2H),2.41(dt,J=1.3Hz?and?6.3Hz,2H),1.96(m,2H),1.64-1.84(m,4H).

Above-mentioned preparation embodiment 1,2,6,7 and 11 method can be used for preparing the following product that contains phenylbenzene.

Contrast R isomer m.p. (℃)/further feature I HOCH ₂C ≡ C R.S 130 II HOCH ₂C ≡ C S ¹H NMR (300MHz, CDCl ₃) δ 8.02 (d, J=

8.4Hz,2H),7.67(d,J=8.7Hz,2H),7.58

(d,J=8.7Hz,2H),7.53(d,J=8.4Hz,2H).

7.17-7.33(m,5H),4.54(s,2H),3.46(dd,J

=8.1,16.8Hz,1H),3.02-3.14(m,2H),2.65

(t,J=7.2Hz,2H),1.64-1.84(m,4H),Ⅲ???HOCH ₂C≡C??????????????R? ¹H?NMR(300MHz,CDCl ₃)δ8.02(d,J=

8.4Hz,2H),7.67(d,J=8.7Hz,2H),7.58

(d,J=8.7Hz,2H),7.53(d,J=8.4Hz,2H),

7.17-7.33(m,5H),4.54(s,2H),3.46(dd,J

=8.1,16.8Hz,1H),3.02-3.14(m,2H),2.65

(t,J=7.2Hz,2H),1.64-1.84(m,4H).Ⅳ???MeOCH ₂C≡C??R.S???????????????????????????136Ⅴ?(n-Pr) ₂NCH ₂C≡C?????R.S?????MS(FAB-LSIMS)510[M+H] ^-Ⅵ??CH ₁CO ₂CH ₂C≡C????R.S?????????????????????137Ⅶ??EtOCO ₂CH ₂C≡C??????R.S?????MS(FAB-LSIMS)499[M+H] ^-Ⅷ??HO(CH ₂) ₂C≡C???????R.S????????????????????124Ⅸ?CH ₃CO ₂(CH ₂) ₂C≡C?R.S?MS(FAB-LSIMS)483[M+H] ^-Ⅹ?HO ₂C(CH ₂) ₂C≡C????R.S?????????????????????184Ⅺ??OHC(CH ₂) ₃C≡C?????R.S?????? ¹H?NMR(300MHz,CDCl ₃)δ9.70(t,J=

1.3Hz,1H),8.05(d,J=8.4Hz,2H),7.70

(d,J=8.4Hz,2H),7.65(d,J=8.4Hz,2H),

7.44(d,J=8.4Hz,2H),7.15-7.35(m,5H),

3.46(dd,J=8.1,16.8Hz,1H),3.14-3.02

(m,2H),2.67(t,J=7.2Hz,2H),2.48(t,J

=7.5Hz,2H),2.41(dt,J=1.3Hz?and6.3

Hz, 2H), 1.96 (m, 2H), 1.64-1.84 (m, 4H). XII HO (CH ₂) ₄C ≡ C R.S 123 X III PhC ≡ C R.S 154 X IV 3-HO-PhC ≡ C R.S 237 embodiment 15 preparation compound X V

Step 1 with NaH (4.35g, fresh distillatory THF (100ml) solution 181mmol) be cooled to 0 ℃ and use by dropping funnel in 40 minutes with commercially available propanedioic acid diallyl (35.0,190mmol) handle.Stir under the room temperature after 30 minutes, (43.9g is 247mmol) in this solution and heat this mixture to refluxing for disposable adding N-(2-bromotrifluoromethane) phthalimide.After 48 hours, cool off this solution to 0 ℃, with 2N HCl quenching and be concentrated to about 20% of its initial volume.Dilute this extract also with saturated K with ethyl acetate (300ml) ₂CO ₃With NaCl aqueous solution continuous washing.With this organic layer MgSO ₄Drying is filtered and concentrating under reduced pressure.Obtain 2-phthalyl imido ethyl malonic acid diallyl (41.2g, 64%), colorless oil with flash column chromatography (with 5-25% ethyl acetate-hexane gradient wash-out) purifying. ¹H?NMR(300MHz,CDCl ₃)δ7.82(m,2H),7.72(m,2H),5.85(m,2H),5.30(m,2H),5.22(m,2H),4.60(m,4H),3.80(t,J=6.6Hz,2H),3.46(t,J=7.2Hz,1H),2.30(dd,J=13.8,6.9Hz,2H)。

Step 2 step 1 product (5.20g, fresh distillatory THF (100ml) solution 14.6mmol) is cooled to 0 ℃, slow simultaneously adding NaH (385mg, 16.1mmol).After 40 minutes, this reaction mixture temperature to room temperature, is added embodiment 1 step 2 (4.55g, product 14.6mmol), and stirred this mixture 24 hours in batches.This reaction mixture is cooled to 0 ℃, with slowly quenching of 2NHCl (300ml), with the dichloromethane extraction of 1 * 100ml methylene dichloride and 2 * 100ml.Use MgSO ₄Drying is somebody's turn to do the organic phase that merges, and filters and concentrate to obtain the required product of 6.50g (71%), and it need not purifying and is used for step 3.TLC (30% ethyl acetate-hexane): R _f=0.4 Step 3 with the product of step 2 (6.50g, 10.4mmol) 1,4-diox (100ml) solution is cooled to 0 ℃, add in succession simultaneously tetrakis triphenylphosphine palladium (0.180g, 146mmol) and tetramethyleneimine (2.40ml, 29.2mmol).After stirring 2 hours under 0 ℃, and at room temperature 4 hours, this reaction mixture is injected 2NHCl (100ml).With the mixture of the dichloromethane extraction gained of 4 * 100ml, use MgSO ₄The organic phase of dry this merging and the concentrated yellow solid diacid (9.70g) that obtains.This material sample of 3.8g is dissolved in 1,4-diox (150ml) and reflux 1 hour.After being cooled to room temperature, this solution of shrinkage and on 300g silica gel this residue of chromatogram (5%-15% methyl alcohol-methylene dichloride) obtain required acid (0.300g), it obtains the required product of the white crystalline solid of 0.170g (total recovery from step 2 is 59%) by recrystallization purifying.MP290-210℃。 Step 4 will be furnished with diaphragm of rubber and argon gas pin inlet and be contained the neck of 2ml THF, and 100ml, round-bottomed flask charge into NaH (435mg, 17.2mmol) and be cooled to 0 ℃, simultaneously by syringe in about 5 minutes, add propargyl alcohol (1.0ml, 0.963g, 17.2mmol).0 ℃ was down stirred this gained mixture 10 minutes and at room temperature 30 minutes, and (1.8ml, 2.59g 15.1mmol), stirred this reaction mixture 36 hours under the room temperature, injected pentane (150ml), and with the salt water washing of 100ml part to add bromotoluene.Distillation is removed this solvent and this residue (3.5g yellow oil) is directly used in step 5. ¹H NMR (300MHz, CDCl ₃) δ 7.36-7.31 (m, 5H), 4.61 (s, 2H), 4.17 (d, J=2.4Hz, 2H), 2.47 (t, J=2.4Hz, 1H). Step 5 is with embodiment 1, and the method for step 5 prepares the compound of embodiment 15 as parent material with the product of step 4 and 3.MP151℃。

Embodiment 16 preparation compound X VI

Step 1 will be furnished with a neck of diaphragm of rubber and argon gas pin inlet, 100ml, round-bottomed flask charge into propargyl alcohol (1.0ml, 0.963g, 17.2mmol), ether (20ml), and be cooled to 0 ℃, slowly add simultaneously NaH (435mg, 17.2mmol).Stir the mixture one hour of this gained under the room temperature, and add tert-butyldimethylsilyl chloride (2.60g, 17.2mmol).Stirred this reaction mixture 6 hours under the room temperature, inject hexane (150ml), and wash with 1N HCl.With this organic phase MgSO ₄Dry also concentrating obtains the 2.88g yellow oil, and it need not purifying and is used for step 2.

2 steps 2 embodiment 1, the method for step 2 prepares required acetyl phenylbenzene with commercially available 4-iodine phenylbenzene and Acetyl Chloride 98Min..TLC (10% ethyl acetate-hexane): R _f=0.3

Step 3 embodiment 1, the method for step 5 utilizes the product of step 1 and 2 to prepare required dibenzenyl.TLC (10% ethyl acetate-hexane): R _f=0.4.

Step 4 will be furnished with a neck of diaphragm of rubber and argon gas pin inlet, 50ml, round-bottomed flask charges into 5mlTHF, the product of step 3 (1.06g, 2.94mmol), and be cooled to-78 ℃ and by syringe drip hexamethyldisilane nitrine potassium (617mg, 2.94mmol).Stirred this reaction mixture 30 minutes down at-78 ℃, (0.374ml, 0.320g 2.94mmol), and stirred this gained mixture 3 hours under-78 ℃ to drip trimethyl silane chlorine by syringe.With this reaction mixture temperature to 0 ℃, one hour, add N-bromine succinimide (0.540g, 2.94mmol), and with this mixture temperature to room temperature and stirred 16 hours.This reaction mixture is injected the saturated NH of 100ml part ₄The Cl aqueous solution and with the dichloromethane extraction of 3 * 50ml.The organic phase MgSO of this merging ₄Dry and concentrated.Column chromatography on 200g silica gel (with 0-5% ethyl acetate-hexane) gradient elution) obtains 0.264g (20%) brooethyl ketone.TLC (10% ethyl acetate-hexane): R _f=0.5. Step 5 is utilized embodiment 15, and the method for step 2-3 and the product of step 4 prepare required phenylbenzene phthalic imidine.TLC (50% ethyl acetate-hexane contains 1% acetate): R _f=0.3

Step 6: will be furnished with in the round-bottomed flask of single neck 50ml of diaphragm of rubber and argon gas pin inlet and charge into 10mlCH ₂Cl ₂, step 5 product (0.040g, 0.067mmol) and 2ml HF-pyridine.At room temperature stir the mixture 10 minutes of this gained, with the water dilution of 75ml part, and with the CH of 75ml part ₂Cl ₂Extraction.This organic phase MgSO ₄Dry and concentrated.Column chromatography on 5g silica gel (25% ethyl acetate-hexane contains 1%HOAc) obtains the product of 6mg (19%) embodiment 16.MP145℃。

Embodiment 17

The P218 of the Biological Detection MMP inhibitor of The compounds of this invention extinguishes fluorescent test

It is at first by C.G.Knight etc. that P218 extinguishes fluorescent test (P218 quenched fluorescence assay) (little photofluorometer profile analysis test (profilingassag)), FEBS Letters, 297,163-266 (1992) is described, in cuvette for the modification of related substrates and many matrix metalloproteinases (MMP) test.This is tested with each embodiment compound of the present invention and three kinds of MMP, MMP-3, and MMP-9 and MMP-2 carry out, and are suitable at 96-hole droplet plate and Hamilton AT ^Following analysis abreast in the workstation.P218 fluorophore substrate (Fluorogenic Substrates)

P218 contains 4-ethanoyl-ayapanin (MCA) group at the N-end position, and contains 3-(2, the 4-dinitrophenyl)-(L)-2 in inside, the synthetic substrate of 3-diamino propionyl (DPA) group.This is used as the modifier of the peptide of matrix metalloproteinase substrate by Knight (1992) report.In case P218 peptide cracking (infer on the Ala-Leu key cut off site), the fluorescence of MCA group can be detected on photofluorometer, excites at 328nm, launches at 393nm.P218 is at present by BACHEMBioscience, and Inc. produces without competition for Bayer Corp.P218 has following structure: H-MCA-Pro-Lys-Pro-Leu-Ala-Leu-DPA-Ala-Arg-NH ₂(MW 1332.2) recombinant human CHO stromelysins (MMP-3):

Recombinant human CHO Pro-MMP-3: people CHO Pro-stromelysin 257 (pto-MMP-3) are as T.J.Housley etc., journal of biological chemistry, and 268,4481-4487 (1993) is described to be expressed and purifying.

The activation of Pro-MMP-3: Pro-MMP-3 with 1.72 μ M (100 μ g/mL) at 5mM Tris by pH7.5; 5mM calcium chloride; in the MMP-3 activation damping fluid that 25mM sodium-chlor and 0.005%Brij-35 form with TPCK (N-methylsulfonyl-(L)-phenylalanine chloromethyl ketone) trypsin 1: 100w/w is to pro-MMP) activate 25 ℃ of incubations 30 minutes.Reaction is by adding Trypsin inhibitor SBTI (SBTI; 5: 1w/w is to trypsinase concentration) and stop.This activatory method causes the formation of the active MMP-3 of 45kDa, and it also contains the C-end parts of enzyme.The preparation people Pro-gelatin enzyme A (MMP-2) of recombinating:

According to R.Fridman etc., journal of biological chemistry, 267,15398-405, the method for (1992) prepares the people Pro-MMP-2 that recombinates with the bovine vaccine expression system: people pro-gelatin enzyme A (Pro-MMP-2).

The Pro-MMP-2 of the activation of Pro-MMP-2: 252mg/mL is at the 25mM Tris by pH7.5, and 5mM calcium chloride dilutes 1: 5 to ultimate density 50mg/mL in the MMP-2 activation damping fluid that 150mM sodium-chlor and 0.005%Brij-35 form.P-aminophenyl mercury acetate (APMA) prepares in 0.05N sodium hydroxide with 10mM (3.5mg/mL).Add APMA solution with 1/20 reaction volume, making final APMA concentration is 0.5mM, with enzyme 37 ℃ of incubations 30 minutes.With activatory MMP-2 (15mL) to 2L MMP-2 activation damping fluid (permeable membrane was used the solution pre-treatment is made up of 0.1%BSA in the MMP-2 activation damping fluid 1 minute, then thoroughly washed).With enzyme the Centricon thickener (thickener also use by MMP-2 activation damping fluid in the solution pre-treatment formed of 0.1%BSA 1 minute, then washing is washed with MMP-2 activation damping fluid then), redilution then repeats twice of reconcentration.Enzyme is diluted to 7.5mL (initial volume 0.5 times) with MMP-2 activation damping fluid.The preparation people Pro-gelatinase B (MMP-9) that recombinates:

Will be with baculovirus protein matter expression system as S.M.Wilhelm etc., journal of biological chemistry, 264,17213-17221 (1989) is described from the U937 cDNA deutero-people Pro-MMP-9 that recombinates: the people Pro-gelatinase B (Pro-MMP-9) that recombinates is expressed as entirely-microscler formula.Should before-enzyme is used by M.S.Hibbs etc., journal of biological chemistry, 260, the described method purifying of 2493-500 (1984).

The activation of Pro-MMP-9: at 50mM Tris by pH7.4,150mM sodium-chlor, 10mM calcium chloride, Pro-MMP-9 (20 μ g/mL) in the MMP-9 activation damping fluid of forming with 0.005%Brij-35 activates with 0.5mM p-aminophenyl mercury acetate (APMA) incubation 3.5 hours by at 37 ℃.The damping fluid dialysis that this enzyme is same relatively and remove APMA.Instrument:

Hamilton Microlab AT Plus ^: MMP-profile analysis test Hamilton MicrolabAT Plus ^Automatization is carried out.Hamilton is programmed to: (1) uses automatic serial dilution to 11 potential inhibitor of the 2.5mM stock solution of inhibitor in 100%DMSO; (2) substrate is distributed in the Cytofluor plate of 96-hole the agent of inoculation dispensing inhibiting; (3) in plate, add single enzyme, mix to start reaction.The successive plates of each additional enzymes is preparation automatically by the moment start-up routine that adds at substrate, again with the inhibitor mixed of diluting, starts reaction by adding enzyme, and by this way, all MMP tests all use identical inhibitor diluent to carry out.

Millipore Cyofluor II: after the incubation, with plate reading on Cytofluor II fluorescence reader, this reader excites at 340nm, and in the 395nm emission, amplification places 80.Damping fluid:

Little photofluorometer reaction buffer (MRB): the test compound that is used for little photofluorometer test, the diluent of enzyme and P218 substrate is at 50mM 2-(N-morpholino) ethyl sulfonic acid (MES) and 10mM calcium chloride by pH6.5, preparation in little photofluorometer reaction buffer (MRB) that 150mM sodium-chlor and 0.005%Brij-35 and 1%DMSO form.Method:

The little photofluorometer profile analysis test of MMP.This is tested with final P218 concentration 6 μ M, and about 0.5 to 0.8nM activatory MMP (every 96-orifice plate 1MMP) and variable inhibitor concentration are carried out.Hamilton Microlab AT Plus ^Be programmed in test, store (100%DMSO) serial dilution to 11 compound from 2.5mM, the 10-of extremely final compound concentration doubly.Beginning, instrument is transported to little photofluorometer reaction buffer (MRB) of various amounts in the 1mL Marsh dilution tube of 96-pipe support.This instrument is got 20 μ L inhibitor (2.5mM), and it is mixed with A row's damping fluid in the Marsh frame, produces the inhibitor concentration of 50 μ M.This inhibitor is diluted to 10,5,1,0.2 then serially, 0.05 and 0.01 μ M.The DMSO that on the position 1 of specimen holder, only contains " the enzyme is only arranged " hole that is useful in the test, this causes at the 1st row, and A drains among the H row does not have inhibitor.Instrument distributes 107 μ L P218 then to the Cytofluor droplet plate of single 96-hole.With the instrument remix, and the A from the Marsh frame drains into the compound of G row loading 14.5 μ L dilution to the corresponding row of droplet plate.(H row's expression " background " row.Replace medicine or enzyme toward wherein adding the little photofluorometer reaction buffer of 39.5 μ L).In each hole, get rid of H row, " background " row by enzyme the reagent storage tank of handling from BSA-that 25 μ L are suitable (finally 5.86 times of enzyme concn).(the enzyme storage tank is used in the 1%BSA pre-treatment at room temperature 1 hour among the 50mM Tris of the pH7.5 that contains 150mM sodium-chlor, then water thorough washing, and at room temperature dry).

After adding enzyme and mixing, this plate is covered 37 ℃ of incubations 25 minutes.Additional enzyme is tested by starting the Hamilton program in an identical manner, the P218 substrate is distributed in the droplet plate, then remix, and from the identical Marsh frame with medicament distribution to the droplet plate.Then second kind of (or the third, or the like) underproof MMP is assigned on the droplet plate from reagent rack, mixes covering then and incubation.

IC in little photofluorometer test ₅₀Measure: launched on the page or leaf by Excel from " CSV " file copy of output to the householder in the data that produce on the Cytofluor II.Calculated simultaneously from the data that various MMP (96-orifice plate of each MMP) obtain.The inhibition percentage ratio of each drug level is measured with the amount of hydrolysis (flat fluorescent that hydrolysis produced in the time of 25 minutes) in " enzyme is only arranged " hole in 1 row by the hole of relatively containing compound.Subtracting background, following calculating suppresses percentage ratio:

((control value-processing value)/control value) * 100 are for inhibitor concentration 5,1, and 0.5,0.1,0.02,0.005 and 0.001 μ M measures and suppresses percentage ratio.Inhibition percentage ratio is used to obtain IC to the logarithmic linear regression analysis of inhibitor concentration ₅₀Value.

The table II

Contrast .#	MMP-3 fluorophore IC-50	MMP-9 fluorophore IC-50	MMP-2 fluorophore IC-50
				???Ⅰ	???????21	??????106	???????4
???Ⅱ	?????2184	???Ⅰ=35％	?????252
				???Ⅲ	????????5	???????37	???????1
???Ⅳ	???????38	??????704	??????21
				???Ⅴ	??????327	?????2630	?????235
???Ⅵ	???????36	??????834	??????14
				???Ⅶ	???????67	?????2460	?????103
???Ⅷ	???????32	??????122	???????6
				???Ⅸ	???????57	??????542	??????37
???Ⅹ	??????203	???Ⅰ=27％	?????108
				???Ⅺ	?????1730	???Ⅰ=24％	?????596
???Ⅻ	???????56.6	??????614	??????36
				??ⅩⅢ	??????405		?????245
??ⅩⅣ	??????125	???Ⅰ=46％	??????85
				??ⅩⅤ	???????11	???????40	???????5
??ⅩⅥ	????????4	????????2	???????1

Other scheme of the present invention is considered specification sheets of the present invention disclosed herein or enforcement, will be conspicuous for those skilled in the art.Specification sheets and embodiment are considered to illustrative just, and the real scope and spirit of the present invention provide in claims.

Ph herein is a phenyl, and Me is a methyl, and THF is a tetrahydrofuran (THF), and Bu is a butyl, and tRu is the tertiary butyl, and Et is an ethyl.

Claims (7)

1. matrix metalloproteinase suppresses compound, has general formula:

Wherein

R ¹⁵Be selected from: HOCH ₂, MeOCH ₂, (n-Pr) ₂NCH ₂, CH, CO ₂CH ₂.EtOCO ₂CH ₂, HO (CH ₂) ₂, CH ₃CO ₂(CH ₂) ₂, HO ₂C (CH ₂) ₂, OHC (CH ₂) ₃, HO (CH ₂) ₄, Ph.3-HO-Ph. and PhCH ₂OCH ₂And R ¹⁶Be selected from:

2. the composition that has matrix metalloproteinase inhibitory activity comprises the compound and the pharmaceutical carrier of claim 1.

3. the method for matrix metal proteinase activity in the inhibition mammalian body comprises the matrix metallo-proteinase inhibitor that this Mammals is given the claim 1 of significant quantity.

4. the method for claim 3, wherein said Mammals is the people.

5. treat mammiferous method, comprise the compound that Mammals is given the claim 1 of matrix metalloproteinase amount of suppression, be enough to:

(a) alleviate osteoarthritis, rheumatoid arthritis, septic arthritis, periodontal disease, keratohelcosis, proteinuria, aneurysmal arotic disease, malnutritive epidermolysis blister, the illness that causes inflammatory reaction, by the osteopenia of the active mediation of MMP, temporomandibular joint bone and joint diseases, or neural demyelination;

(b) cartilage of the retardance of the metastases that causes of wound type joint injury or sex change loss;

(c) reduce the Coronary thrombosis that causes by atherosclerotic plaque rupture; Or

(d) realize Birth control.

6. the method for claim 5, wherein said effect is to alleviate osteoarthritis.

7. the method for claim 5, wherein said effect are the retardance metastases.